Stroke

Stroke Therapeutics is a biotechnology company focused on developing transformative RNA-based therapies for the treatment of stroke and other neurological disorders. The company utilizes its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to develop antisense oligonucleotides (ASOs) that can increase the expression of specific proteins by modulating non-productive splicing. Their lead programs aim to address the underlying genetic and physiological causes of ischemic stroke and Dravet syndrome. By targeting gene expression at the RNA level, Stroke Therapeutics seeks to provide long-lasting neuroprotection and functional recovery for patients with limited treatment options.